1-3 of 3
Samantha Depadova
Close
Sort by
Journal Articles

TP53 Mutations Determine Outcome of Patients (pts) with High-Risk Myelodysplastic Syndrome (HRMDS) and Acute Myelogenous Leukemia (AML) Regardless of Karyotype and ELN Risk Stratification

James K. McCloskey, MD, Marshall McKenna, BA, Jamie L. Koprivnikar, MD, Samantha Depadova, Genique Stanislaus, ANP, Stuart L. Goldberg, MD, Stefan Faderl, MD
Journal: Blood
Blood (2016) 128 (22): 5242.
https://doi.org/10.1182/blood.V128.22.5242.5242
Published: 2016
Journal Articles

Outcome of Acute Myeloid Leukemia (AML) Induction Therapy Based on D14 Marrow Biopsy According to European Leukemia Net (ELN) Risk Classification

David Ray, PharmD, MBA, Jamie L. Koprivnikar, MD, James K. McCloskey, MD, Genique Stanislaus, ANP, Christina Howlett, PharmD, BCOP, Amy Davidow, PhD, Samantha Depadova, Stuart L. Goldberg, MD, Stefan Faderl, MD
Journal: Blood
Blood (2016) 128 (22): 5174.
https://doi.org/10.1182/blood.V128.22.5174.5174
Published: 2016
Journal Articles

Features and Outcome of Patients (Pts) with New Diagnosis of Acute Myeloid Leukemia (AML) with Monocytic Differentiation (AML-Mo) Following Standard Induction Therapy. Do We Need a Different Strategy?

James K. McCloskey, MD, Samantha Depadova, Jamie L. Koprivnikar, MD, Tracy Andrews, MA, Marshall McKenna, BA, Genique Stanislaus, ANP, Stuart L. Goldberg, MD, Stefan Faderl, MD
Journal: Blood
Blood (2016) 128 (22): 4017.
https://doi.org/10.1182/blood.V128.22.4017.4017
Published: 2016